TABLE 1.
Immune molecule(s) | Productionb |
Comments | Reference(s)d | ||
---|---|---|---|---|---|
Respiratory tractc |
Systemic | ||||
Nasal mucosa | Lung | ||||
Th1 cytokines | |||||
IFN-γ | + | + | + | Protective | |
IL-12 | + | + | + | Protective | |
IL-1α and IL-1β | + | + | Deleterious | ||
IL-2 | + | + | + | No reported association with severity | |
TNF-α | + | + | + | Deleterious | |
IL-18 | + | Protective | |||
sCD25 | + | Deleterious | |||
Th2 cytokines | |||||
IL-4 | + | + | + | Deleterious | |
IL-6 | + | + | + | Variable association with severity (see text) | |
IL-9 | + | + | No reported association with severity | ||
IL-10 | + | + | + | Variable association with severity (see text) | |
IL-13 | + | + | + | No reported association with severity | |
Other cytokines | |||||
IL-8 | + | + | + | Deleterious: neutrophil chemoattractant | |
IL-17A | + | + | Variable association with severity (see text) | ||
IL-33 | + | No reported association with severity | 130 | ||
Chemokines | |||||
CCL-2 (MCP-1) | + | + | Deleterious | ||
CCL-3 (MIP-1α) | + | + | Deleterious | ||
CCL-4 (MIP-1β) | + | Variable association with severity (see text) | |||
CCL-5 (RANTES) | + | + | Protective | ||
CXCL-10 (IP-10) | + | + | Deleterious | ||
Eotaxin | + | + | Deleterious | ||
Other | |||||
IFN-λ | + | Deleterious despite stimulating ISG expression | 159, 160 | ||
IFN-α | + | + | No reported association with severity | 158 | |
G-CSF | + | + | Circulating levels are higher in infants with RSV LRTI requiring ventilation | 18, 105 | |
Soluble ICAM-1 | + | + | Levels in nasal fluid positively correlate with severity | 40, 124, 126 | |
Substance P | + | + | Lower concentrations associated with increased severity | 106 | |
MBL | − | No reported association with severity | 44 | ||
Cathelicidin LL-37 | + | Protective: in human exptl infection, higher constitutive nasal levels are associated with reduced development of infection | 177 | ||
Olfactomedin 4 | + | Greater expression in PBMC was associated with need for ventilation in RSV LRTI | 19 | ||
Surfactants A, B, D | − | + | The pulmonary level of surfactant A and measurable surfactant activity increase during recovery | 178–181 | |
MMP-9, MMP-3, PGP | + | Elevated pulmonary levels in ventilated infants are associated with hypoxia and acute lung injury | 182–184 | ||
KL-6 | + | Circulating levels are greater in infants with RSV LRTI requiring ventilation | 185 | ||
sTRAIL | + | No reported association with severity | 186 |
Abbreviations: CCL, C-C motif chemokine ligand; CXCL, C-X-C motif chemokine ligand; G-CSF, granulocyte colony-stimulating factor; ICAM, intercellular adhesion molecule; IFN, interferon; IL, interleukin; IP-10, IFN-γ-inducible protein-10; ISG, interferon-stimulated gene; MBL, mannose binding lectin; MCP-1, monocyte chemoattractant protein-1; MIP, macrophage inflammatory protein; MMP, matrix metalloproteinase; PGP, proline-glycine-proline (the product of MMP hydrolysis of collagen); RANTES, regulated on activation, normal T expressed and secreted; sTRAIL, soluble TNF-related apoptosis-inducing ligand; TIMP, tissue inhibitor of metalloproteinase; TNF, tumor necrosis factor.
+, increased production; −, reduced production.
Nasal mucosa, measurements made in nasal fluid or nasopharyngeal aspirate; lung, measurements made in bronchoalveolar lavage fluid or tracheal aspirate.
References are provided for molecules not discussed in detail in the text.